Positron Emission Tomography in Oncology: A Review

Clinical Oncology

Volumn 19, Issue 4, 2007, Pages 237-255

  Wood, K A ^a,b   Hoskin, P J ^a,b   Saunders, M I ^a,b  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Diagnosis; malignancy; PET; PET CT; radiotracer; staging

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 NITROIMIDAZOLE DERIVATIVE; 5 HYDROXYTRYPTOPHAN C 11; ACETIC ACID C 11; ADRENALIN C 11; ANTINEOPLASTIC AGENT; CHOLINE C 11; ECTOMIDATE C 11; FLUORINE 18; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROPHENYLALANINE F 18; FLUORODIHYDROTESTOSTERONE F 18; FLUORODOPAMINE F 18; FLUOROESTRADIOL F 18; HYDROXYEPHEDRINE C 11; INTEGRIN; MATRIX METALLOPROTEINASE INHIBITOR; METHIONINE C 11; METHYLSPIPERONE C 11; METOMIDATE C 11; MONOCLONAL ANTIBODY; PENTETREOTIDE IN 111; PHENYLEPHRINE C 11; PLATINUM COMPLEX; PROSTATE SPECIFIC ANTIGEN; RACLOPRIDE C 11; THIOSEMICARBAZONE DERIVATIVE; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; ADRENAL TUMOR; APOPTOSIS; ARTICLE; ASPIRATION BIOPSY; BLADDER CANCER; BONE METASTASIS; BONE SCINTISCANNING; BRAIN CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARCINOID; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE FREE SURVIVAL; DRUG EXCRETION; DRUG METABOLISM; DRUG UPTAKE; ENDOMETRIUM CANCER; ESOPHAGUS TUMOR; FALSE POSITIVE RESULT; GERM CELL TUMOR; HEAD AND NECK TUMOR; HODGKIN DISEASE; HUMAN; HYPOXIA; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHOMA; MAMMOGRAPHY; MELANOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PHEOCHROMOCYTOMA; PNEUMOTHORAX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; SOFT TISSUE METASTASIS; SOFT TISSUE SARCOMA; SURVIVAL TIME; THYROID CARCINOMA; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER;

EVIDENCE-BASED MEDICINE; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 34047269955     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.02.001     Document Type: Article

References (144)

1. Schoder H., Erdi Y.E., Larson S.M., and Yeung H.W.D. PET-CT: a new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging 30 (2003) 1419-1437
2. Gambhir S.S., Czernin J., Schwimmer J., Silverman D.H., Coleman R.E., and Phelps M.E. A tabulated summary of the FDG PET literature. J Nucl Med 42 (2001) 1S-93S
3. Lardinois D., Weder W., Hany T.F., et al. Staging of non-small cell lung cancer with integrated positron emission tomography and computed tomography. N Engl J Med 348 (2003) 2500-2507
4. Filmont J.-E., Czernin J., Yap C., et al. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 124 (2003) 608-613
5. Torizuka T., Nakamura F., Kanno T., et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 31 (2004) 22-28
6. Lavely W.C., Delbeke D., Greer J.P., et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin's and non-Hodgkin's lymphoma after first line chemotherapy. Int J Radiat Oncol Biol Phys 57 (2003) 307-315
7. British Nuclear Medicine Society. Standards for delivering a PET service within the UK - A report of the Intercollegiate Standing Committee on Nuclear Medicine. Policy Document. March 2005.
8. Price P., and Laking G. How should we introduce clinical PET in the UK? The oncologists need to have a view. Clin Oncol (R Coll Radiol) 16 3 (2004) 172-175
9. Royal College of Radiologists. PET-CT in the UK: a strategy for development and integration of a leading edge technology within routine clinical practice (August 2005). www.rcr.ac.uk/docs/general
10. Warburg O. The metabolism of tumours (1931), Richard R Smith, New York 129-169
11. Brown R.S., Leung J.Y., Kison P.V., Zasadny K.R., Flint A., and Wahl R.L. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 40 (1999) 556-565
12. Higashi K., Ueda Y., Sakurai A., et al. Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell cancer. Eur J Nucl Med 27 (2000) 1778-1785
13. Brink I., Reinhardt M.J., Hoegerle S., Altehoefer C., Moser E., and Nitzsche E.U. Increased metabolic activity in the thymus gland studied with (18)F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med 42 (2001) 591-595
14. Macapinlac H. The utility of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma. Mol Imaging Biol 6 4 (2004) 200-207
15. Chapman J.D., Baer K., and Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res 43 (1983) 1523-1528
16. Apisarnthanarax S., and Chao K.S.C. Current imaging paradigms in radiation oncology. Radiat Res 163 (2005) 1-25
17. Piert M., Machulla H.J., Schwaiger M., et al. Hypoxia-specific tumour imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 46 1 (2005) 106-113
18. Fujibayshi Y., Taniuchi H., Yonekura Y., Ohtani H., Konishi J., and Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 38 (1997) 1155-1160
19. 64Cu-ATSM in vitro and in vivo in a hypoxic tumour model. J Nucl Med 40 (1999) 177-183
20. Dehdashti F., Mintun M.A., Siegel B.A., et al. In vivo assessment of tumour hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 30 6 (2003) 844-850
21. Dehdashti F., Grigsby P.W., Mintun M.A., Lewis J.S., Siegel B.A., and Welch M.J. Assessing tumour hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response - a preliminary report. Int J Radiat Oncol Biol Phys 55 5 (2003) 1233-1238
22. Halter G., Buck A.K., Schirrmeister H., et al. [18F]3-deoxy-3-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?. J Thoracic Cardiovasc Surg 127 (2004) 1093-1099
23. Francis D.L., Freeman A., Ell P.J., et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 52 (2003) 1602-1606
24. Kubota R., Kubota K., Yamada S., et al. Methionine uptake by tumour tissue: a microautoradiographic comparison with FDG. J Nucl Med 36 (1995) 484-492
25. Nunez R., Macapinlac H.A., Larson S.M., et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43 1 (2002) 46-55
26. Ishimori T., Saga T., Nagata Y., et al. 18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med 18 (2004) 669-674
27. Kurhanewicz J., Vigneron D.B., and Nelson S.J. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2 (2000) 166-189
28. Hara T., Kosaka N., and Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39 (1998) 990-995
29. Tian M., Zhang H., Oriuchi N., Higuchi T., and Endo K. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumours. Eur J Nucl Med Mol Imaging 31 (2004) 1064-1072
30. Yoshimoto M., Waki A., Yonekura Y., et al. Characterisation of acetate metabolism in tumour cells in relation to cell proliferation: acetate metabolism in tumour cells. Nucl Med Biol 28 (2001) 112-122
31. Weber W.A. Positron emission tomography as an imaging biomarker. J Clin Oncol 24 20 (2006) 3282-3292
32. Pacak K., Eisenhofer G., and Goldstein D.S. Functional imaging of endocrine tumours: role of positron emission tomography. Endocr Rev 25 4 (2004) 568-580
33. Langsteger W., Heinisch M., and Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 36 1 (2006) 73-92
34. Partridge S., Timothy A., O'Doherty M.J., Hain S.F., Rankin S., and Mikaeel G. Fluorodeoxyglucose positron emission tomography and the pretreatment staging of Hodgkin's disease. Ann Oncol 11 (2000) 1273-1279
35. Moog F., Kotzerke J., and Reske S.N. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 40 (1999) 1407-1413
36. Carr R., Barrington S.F., Madan B., et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91 (1998) 3340-3346
37. O'Doherty M.J., MacDonald E.A., Barrington S.F., Mikhaeel N.G., and Schey S. Positron emission tomography in the management of lymphomas. Clin Oncol 14 (2002) 415-426
38. Young C.S., Young B.L., and Smith S.M. Staging Hodgkin's disease with 18-FDG-PET: comparison with CT and surgery. Clin Positron Imaging 1 (1998) 161-164
39. Spaepen K., Stroobants S., Dupont P., et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol 19 2 (2001) 414-419
40. Mikhaeel N.G., Timothy A.R., O'Doherty M.J., Hain S., and Maisey M.N. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma. Leukaemia Lymphoma 39 (2000) 543-553
41. Spaepen K., Stroobants S., Dupont P., et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13 (2002) 1356-1363
42. Mikhaeel N.G., Hutchings M., Fields P.A., O'Doherty M.J., and Timothy A.R. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16 9 (2005) 1514-1523
43. Hutchings M., Loft A., Specht L., et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107 1 (2006) 53-59
44. Wong W., Campbell H., and Saunders M. Positron emission tomography (PET) - evaluation of 'indeterminate pulmonary lesions'. Clin Oncol 14 (2002) 123-128
45. Prauer H.W., Weber W.A., Romer W., Treumann T., Ziegler S.I., and Schwaiger M. Controlled prospective study of positron emission tomography using the glucose analogue [18F]fluorodeoxyglucose in the evaluation of pulmonary nodules. Br J Surg 85 (1998) 1506-1511
46. Dewan N.A., Reeb S.D., Gupta N.C., Gobar L.S., and Scott W.J. PET FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. Chest 108 (1995) 441-446
47. Van Tinteren H. The implementation of PET in non-small-cell lung cancer in the Netherlands. Clin Oncol (R Coll Radiol) 18 (2006) 156-157
48. Detterbeck F.C., Falen S., Rivera M.P., Halle J.S., and Socinski M.A. Seeking a home for a PET, part 1: defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses. Chest 125 (2004) 2294-2299
49. Gould M.K., Kuschner W.G., Owens D.K., et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 139 (2003) 879-892
50. Sasaki R., Komaki R., Macapinlac H., et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23 (2005) 1136-1143
51. Weber W.A., Petersen V., Schwaiger M., et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21 (2003) 2651-2657
52. MacManus M.R., Hichs R., Ball D.L., et al. FDG-PET-detected extracranial metastasis in patients with non-small-cell lung cancer undergoing staging for surgery or radical radiotherapy: survival correlates with metastatic disease burden. Acta Oncol 42 (2003) 48-54
53. Bradley J., Thorstad W.L., Bertrand R.J., et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 59 (2004) 78-86
54. Blum R., MacManus M.P., Rischin D., Michael M., Ball D., and Hicks R.J. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol 27 (2004) 167-171
55. Wong W.L., and Saunders M. The impact of FDG PET on the management of occult primary head and neck tumours. Clin Oncol (R Coll Radiol) 15 8 (2003) 461-466
56. Adams S., Baum R., and Stuckensen T. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 25 (1998) 1255-1260
57. Wong R.J., Lin D.T., and Schoder H. Diagnostic and prognostic value of [18(F)]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 20 (2002) 4199-4208
58. Lonneux M., Lawson G., and Ide C. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumour recurrence in the symptomatic patient. Laryngoscope 110 (2000) 1492-1497
59. Avril N., Rose C.A., Schelling M., et al. Breast imaging with positron emission tomography and [fluorine-18]-fluorodeoxyglucose: use and limitations. J Clin Oncol 18 (2000) 3495-3502
60. Adler L.P., Crowe J.P., Al-Kaisi N.K., and Sunshine J.L. Evaluation of breast masses and axillary lymph nodes with [F-18]-2-deoxy-2-fluoro-D-glucose PET. Radiology 187 (1993) 743-750
61. Avril N., Dose J., Janicke F., and Sunshine J.L. Metabolic characterisation of breast tumours with positron emission tomography using [F-18]-fluorodeoxyglucose. J Clin Oncol 14 (1996) 1848-1857
62. Oshida M., Uno K., Suzuki M., et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose. Cancer 82 (1998) 2227-2234
63. Cody III H.S., and Urban J.A. Internal mammary node status: a major prognosticator in axillary node-negative breast cancer. Ann Surg Oncol 2 (1995) 32-37
64. Moon D.H., Maddahi J., Silverman D.H., Glaspy J.A., Phelps M.E., and Hoh C.K. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 39 3 (1998) 431-435
65. Lonneux M., Borbath I., Berliere M., Kirkove C., and Pauwels S. The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 3 (2000) 45-49
66. Hathaway P.B., Mankoff D.A., Maravilla K.R., et al. The value of combined FDG-PET and magnetic resonance imaging in the evaluation of suspected local-regional breast cancer: preliminary experience. Radiology 210 (1998) 807-814
67. Beresford M., Padhani A., Goh V., and Makris A. Imaging breast cancer response during neoadjuvant systemic therapy. Expert Rev Anticancer Ther 5 5 (2005) 893-905
68. Schelling M., Avril N., and Nahrig J. Positron emission tomography using [18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18 (2000) 1689-1695
69. Kim S.J., Kim S.K., Lee E.S., Ro J., and Kang S. Predictive value of [18F]FDG PET for pathological response of breast cancer to neoadjuvant chemotherapy. Ann Oncol 15 (2004) 1352-1357
70. Huddart R.A. Use of FDG-PET in testicular tumours. Clin Oncol (R Coll Radiol) 15 (2002) 123-127
71. Lassen U., Daugaard G., Hojgaard L., Damgaard K., Rorth M., and Eigtved A. Wholebody positron emission tomography (PET) with FDG in patients with stage I non-seminomatous germ cell tumours (NSGCT). Eur J Nucl Med Imaging 30 (2003) 396-402
72. European Germ Cell Cancer Consensus Group (EGCCCG). European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Concensus Group (EGCCCG). Ann Oncol 15 (2004) 1377-1399
73. Kollmansberger C., Oechsle K., Dohmen B.M., et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with non-seminomatous germ cell carcinoma. Cancer 94 (2002) 2353-2362
74. De Santis M., Becherer A., Bokemeyer C., et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumour in postchemotherapy seminoma: ban update of the prospective multicentric SEMPET trial. J Clin Oncol 22 (2004) 1034-1039
75. Carey B.M. Imaging for prostate cancer. Clin Oncol (R Coll Radiol) 17 (2005) 553-559
76. Hermann K., Schoder H., Eberhard S., et al. FDG PET for the detection of recurrent/metastatic prostate carcinoma in patients with rising PSA after radical prostatectomy. J Nucl Med 45 (2004) 359 [abstract]
77. Fricke E., Machtens S., Hofmann M., et al. Positron emission tomography with [11C]acetate and [18F]FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 30 (2003) 607-611
78. Picchio M., Messa C., Landoni C., et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 169 (2003) 1337-1340
79. Nunez R., Macapinlac H.A., Yeung H.W., et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43 (2002) 46-55
80. Oyama N., Akino H., Suzuki Y., et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun 22 (2001) 963-969
81. Ahlstrom H., Malmstrom P.U., Letocha H., Andersson J., Langstrom B., and Nilsson S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Radiology 37 (1996) 180-185
82. de Jong I.J., Pruim J., Elsinga P.H., Jongen M.M., Mensink H.J., and Vaalburg W. Visualisation of bladder cancer using (11)C-choline PET: first clinical experience. Eur J Nucl Med Mol Imaging 29 (2002) 1283-1288
83. Ramdave S., Thomas G.W., Berlangieri S.U., et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 166 (2001) 825-830
84. Kang D.E., White Jr. R.L., Zuger J.H., Sasser H.C., and Teigland C.M. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 171 (2004) 1806-1809
85. Grigsby P.W., Siegel B.A., and Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 19 17 (2001) 3745-3749
86. Wright J.D., Dehdashti F., Grigsby P.W., et al. Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer 104 11 (2005) 2484-2491
87. Grigsby P.W., Siegel B.A., Dehdashti F., Rader J., and Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 22 11 (2004) 2167-2171
88. Belhocine T., De Barsy C., Hustinx R., and Willems-Foidart J. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Med Mol Imaging 29 (2002) 1132-1139
89. Yoshida Y., Kurokawa T., Kotsuji F., et al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. Am J Roentgenol 182 1 (2004) 227-233
90. Kurokawa T., Yoshida Y., Kotsuji F., et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 109 6 (2004) 926-932
91. Bristow R.E., del Carmen M.G., Montz F.J., et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 90 3 (2003) 519-528
92. Ioannidis J.P., and Lau J. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med 44 (2003) 717-724
93. Schwarzbach M.H.M., Hinz U., Buchler M., et al. Prognostic significance of preoperative [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with respectable soft tissue sarcomas. Ann Surg 241 2 (2005) 286-294
94. Jones D.N., McCowage G.B., Coleman R.E., et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 37 9 (1996) 1438-1444
95. Gyorke T., Zajic T., Brink I., et al. Impact of FDG PET for staging of Ewing sarcomas and primitive neurectodermal tumours. Nucl Med Commun 27 1 (2006) 17-24
96. Hawkins D.S., Schuetze S.M., Eary J.F., et al. [18F]fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumours. J Clin Oncol 23 34 (2005) 8828-8834
97. Friedland S., Soetikno R., Carlisle M., Taur A., Kaltenbach T., and Segall G. 18-Fluorodeoxyglucose positron emission tomography has limited sensitivity for colonic adenoma and early stage colon cancer. Gastrintest Endosc 61 (2005) 395-400
98. Gutman F., Alberini J.L., Wartski M., et al. Incidental colonic focal lesions detected by FDG PET/CT. Am J Roentgenol 185 (2005) 495-500
99. Kamel E.M., Thumshirn M., Truninger K., et al. Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 45 (2004) 1804-1810
100. van Kouwen M.C., Nagengast F.M., Jansen J.B., Oyen W.J., and Drenth J.P. 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol 23 (2005) 3713-3717
101. Huebner R.H., Park K.C., Shepherd J.E., et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 41 (2000) 1177-1189
102. Valk P.E., Abella-Columna E., Haseman M.K., et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 134 (1999) 503-511
103. Kalff V., Hicks R.J., Ware, Hogg A., Binns D., and McKenzie A.F. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 43 (2002) 492-499
104. Guillem J.G., Moore H.G., Akhurst T., et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment response to preoperative chemoradiation: a means for determining long term outcomes of rectal cancer. J Am Coll Surg 199 (2004) 1-7
105. Belhocine T.Z., Scott A.M., Even-Sapir E., Urbain J.L., and Essner R. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 47 (2006) 957-967
106. Wagner J.D., Schauwecker D., Daggy J., et al. Inefficacy of F-18 fluorodeoxy-D-glucose positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 104 3 (2005) 570-579
107. Kaschten B., Steveneart A., Reznik M., et al. Preoperative evaluation of 54 gliomas with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39 5 (1998) 778-785
108. Barker II F.G., Chang S.M., Valk P.E., Pounds T.R., and Prados M.D. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 79 1 (1997) 115-126
109. Pauleit D., Floeth F., Tellmann L., et al. Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-α-methyl-L-tyrosine SPECT in brain tumours. J Nucl Med 45 (2004) 374-381
110. Chung J.K., Kim Y.K., Kim S.K., et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 29 (2002) 176-182
111. Jager P.L., Vaalburg W., Pruim J., de Vries E.G., Langen K.J., and Piers D.A. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 42 (2001) 432-445
112. Ogawa T., Inugami A., Hatazawa J., et al. Clinical positron emission tomography for brain tumours: comparison of fluorodeoxyglucose F 18 and L-methyl-11C-methionine. Am J Neuroradiol 17 (1996) 345-353
113. Sasaki M., Kuwabara Y., Mihara F., et al. A comparative study of thallium-201 SPECT, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med 25 (1998) 1261-1269
114. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with [18F]FLT and positron emission tomography. Nat Med 4 (1998) 1334-1336
115. Chen W., Cloughesy T., Silverman D.H., et al. Imaging proliferation in brain tumours with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46 6 (2005) 945-952
116. Choi J.Y., Lee K.H., Kim B.T., et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the oesophagus. J Nucl Med 41 5 (2000) 808-815
117. Flamen P., Lerut A., Van Cutsem E., et al. Utility of positron emission tomography for the staging of patients with potentially operable oesophageal carcinoma. J Clin Oncol 18 18 (2000) 3202-3210
118. Brucher B., Weber W., Schwaiger M., et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233 3 (2001) 300-309
119. Flamen P., Van Cutsem E., Mortelmans L., et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13 (2002) 361-368
120. Chung J.K., So Y., Cho B.Y., et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 40 (1999) 986-992
121. Grunwald F., Kalicke T., Biersack H.J., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26 (1999) 1547-1552
122. Dietlein M., Scheidhauer K., Voth E., Theissen P., and Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 24 (1997) 1342-1348
123. Feine U. Fluor-18-deoxyglucose positron emission tomography in differentiated thyroid cancer. Eur J Endocrinol 138 (1998) 492-496
124. Shulkin B.L., Thompson N.W., Shapiro B., Francis I.R., and Sisson J.C. Phaeochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 222 (1999) 35-41
125. Hoegerle S., Nitzsche E., Neumann H.P., et al. Pheochromocytomas: detection with 18F DOPA whole-body PET - initial results. Radiology 222 (2002) 507-512
126. Eriksson B., Bergstrom M., Orlefors H., Sundin A., Oberg K., and Langstrom B. Use of PET in neuroendocrine tumours. In vivo applications and in vitro studies. Q J Nucl Med 44 (2000) 68-76
127. Hoegerle S., Altehoefer C., Nitzsche E., et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumours. Radiology 220 (2001) 373-380
128. Ciernik I.F., Dizendorf E., Baumert B.G., et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 57 (2003) 853-863
129. Kiffer J.D., Berlangeri S.U., Scott A.M., et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 19 (1998) 167-177
130. Vanuytsel L.J., Vansteenkiste J.F., Stroobants S.G., et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 55 (2000) 317-324
131. van Der Wel A., Nijsten S., Hochstenbag M., et al. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modelling study. Int J Radiat Oncol Biol Phys 61 (2005) 649-655
132. De Ruysscher D., Wanders S., van Haren E., et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 62 (2005) 988-994
133. Bradley J.D., Dehdashti F., Mintun M.A., Govindan R., Trinkaus K., and Siegel B.A. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 22 (2004) 3248-3254
134. Kamel E.M., Zwahlen D., Wyss M.T., Stumpe K.D., von Schulthess G.K., and Steinert H.C. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 44 (2003) 1911-1917
135. Daisne J.F., Duprez T., Weynand B., et al. Tumour volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 233 (2004) 93-100
136. van Baardwijk A., Baumert B., De Ruysscher D., et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 32 (2006) 245-260
137. Schwartz D.L., Ford E., Rajendran J., et al. FDG-PET/CT imaging for preradiotherapy staging of head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 129-136
138. Mutic S., Grigsby P.W., Low D.A., et al. PET-guided three-dimensional treatment planning of intracavitary gynaecologic implants. Int J Radiat Oncol Biol Phys 52 (2002) 1104-1110
139. Malyapa R.S., Mutic S., Low D.A., et al. Physiologic FDG-PET three-dimensional brachytherapy treatment planning for cervical cancer. Int J Radiat Oncol Biol Phys 54 (2002) 1140-1146
140. Tsai C.S., Chang T.C., Lai C.H., et al. Preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes on MRI/CT. Int J Radiat Oncol Biol Phys 58 (2004) 1506-1512
141. Nuutinen J., Sonninen P., Lehikoinen P., et al. Radiotherapy treatment planning and long-term follow-up with (11)Cmethionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 48 (2000) 43-52
142. Tralins K.S., Douglas J.G., Stelzer K.J., et al. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 43 (2002) 1667-1673
143. Solberg T.D., Agazaryan N., Goss B.W., Dahlbom M., and Lee S.P. A feasibility study of 18F-fluorodeoxyglucose positron emission tomography targeting and simultaneous integrated boost for intensity-modulated radiosurgery and radiotherapy. J Neurosurg 101 suppl 3 (2004) 381-389
144. Leong T., Everitt C., Hicks R.J., et al. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol 78 (2006) 254-261